Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

bioAffinity Technologies, Inc. - Common Stock (NQ: BIAF )

3.060 +0.440 (+16.79%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,488,368
Open 2.690
Bid (Size) 2.950 (1)
Ask (Size) 3.030 (1)
Prev. Close 2.620
Today's Range 2.620 - 3.670
52wk Range 1.310 - 15.55
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Dow Rises 80 Points; Altamira Therapeutics Shares Plunge
U.S. stocks traded mixed toward the end of trading, with the Dow Jones gaining around 80 points on Tuesday. The Dow traded up 0.24% to 33,710.06 while the NASDAQ fell 0.21% to 11,340.24. The S&P 500... 
Via Benzinga
Why Baudax Bio Shares Are Trading Higher By 60%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Baudax Bio, Inc. (NASDAQ: BXRX) shares surged 59.7% to $5.03 after the company announced the outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade in... 
Via Benzinga

Performance

YTD
+96.15%
+96.15%
1 Month
+71.91%
+71.91%
3 Month
+11.27%
+11.27%
6 Month
-63.13%
-63.13%
1 Year
-63.13%
-63.13%

More News

Read More
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Is BioAffinity (BIAF) Stock Up 40% Today?
Via InvestorPlace
Dow Edges Higher; Crude Oil Down 1%
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer Treatments
From bioAffinity Technologies, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
bioAffinity Technologies Expands Diagnostic Division with Promotions and New Hires to Strengthen Clinical Bench
From bioAffinity Technologies, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting
From bioAffinity Technologies, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
bioAffinity Technologies Reports Third Quarter 2022 Financial Results and Provides Business Update
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Sheila Habib, MD and David Hill, MD Join the Company’s Scientific and Medical Advisory Board
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies to Report Third Quarter 2022 Financial Results
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Award of Therapeutic Patents in China, Mexico and Australia
From bioAffinity Technologies, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
bioAffinity Technologies Presents Results from Flow Cytometry Analysis of the Lung at CHEST Conference
From bioAffinity Technologies, Inc.
Via Business Wire
Why Amylyx Pharmaceuticals Is Trading Higher By Over 8%; Here Are 22 Stocks Moving Premarket
Via Benzinga
7 Penny Sleeper Stocks to Buy Before Wall Street Wakes Up
Via InvestorPlace
Nasdaq Surges Over 150 Points; Gold Rises 2%
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.